These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34187202)

  • 61. Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis.
    Mavropoulos A; Zafiriou E; Simopoulou T; Brotis AG; Liaskos C; Roussaki-Schulze A; Katsiari CG; Bogdanos DP; Sakkas LI
    Rheumatology (Oxford); 2019 Dec; 58(12):2240-2250. PubMed ID: 31209492
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study.
    Kim SC; Pawar A; Desai RJ; Solomon DH; Gale S; Bao M; Sarsour K; Schneeweiss S
    Semin Arthritis Rheum; 2019 Oct; 49(2):222-228. PubMed ID: 30967248
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US.
    Strand V; Husni E; Griffith J; Zhou ZY; Signorovitch J; Ganguli A
    Rheumatol Ther; 2016 Dec; 3(2):305-322. PubMed ID: 27747584
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry.
    Mease PJ; Lesperance T; Liu M; Collier DH; Mason M; Deveikis S; Accortt NA
    J Rheumatol; 2017 Feb; 44(2):184-192. PubMed ID: 28089969
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of biologics on fatigue in psoriatic arthritis: A systematic literature review with meta-analysis.
    Reygaerts T; Mitrovic S; Fautrel B; Gossec L
    Joint Bone Spine; 2018 Jul; 85(4):405-410. PubMed ID: 29452303
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis.
    Song Y; Betts KA; Lu Y; Singh R; Clewell J; Griffith J
    Rheumatol Ther; 2019 Jun; 6(2):285-297. PubMed ID: 31055779
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use.
    Kaplan D; Husni E; Chang E; Broder MS; Paydar C; Bognar K; Yan J; Richter S; Desai P; Khilfeh I
    J Comp Eff Res; 2022 Jun; 11(8):575-582. PubMed ID: 35514324
    [No Abstract]   [Full Text] [Related]  

  • 68. Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature.
    Garcovich S; Giovanardi G; Malvaso D; De Simone C; Peris K
    Medicine (Baltimore); 2020 Jan; 99(5):e18991. PubMed ID: 32000436
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry.
    Bayaraa B; Imafuku S
    J Dermatol; 2019 May; 46(5):389-398. PubMed ID: 30861182
    [TBL] [Abstract][Full Text] [Related]  

  • 70. New treatment paradigms in psoriatic arthritis: an update on new therapeutics approved by the U.S. Food and Drug Administration.
    Felquer ML; Soriano ER
    Curr Opin Rheumatol; 2015 Mar; 27(2):99-106. PubMed ID: 25633241
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
    Hellgren K; Dreyer L; Arkema EV; Glintborg B; Jacobsson LT; Kristensen LE; Feltelius N; Hetland ML; Askling J;
    Ann Rheum Dis; 2017 Jan; 76(1):105-111. PubMed ID: 27147709
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.
    Haber SL; Hamilton S; Bank M; Leong SY; Pierce E
    Ann Pharmacother; 2016 Apr; 50(4):282-90. PubMed ID: 26783350
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effect of interleukin-17A inhibitor in Japanese patients with psoriatic arthritis compared with tumor necrosis factor-alpha inhibitor.
    Izumiyama T; Mori Y; Oizumi I; Hamada S; Kurishima H; Terui H; Omori-Shimada R; Yamasaki K; Itoi E
    J Orthop Surg (Hong Kong); 2021; 29(2):23094990211012286. PubMed ID: 33938296
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
    J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study.
    Kavanaugh A; McInnes IB; Mease PJ; Hall S; Chinoy H; Kivitz AJ; Wang Z; Mpofu S
    J Rheumatol; 2016 Sep; 43(9):1713-7. PubMed ID: 27307536
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE).
    Iannone F; Santo L; Bucci R; Semeraro A; Carlino G; Paoletti F; Quarta L; Leucci P; Zuccaro C; Marsico A; Scioscia C; D'Onofrio F; Mazzotta D; Muratore M; Cantatore FP; Lapadula G
    Clin Rheumatol; 2018 Mar; 37(3):667-675. PubMed ID: 29411182
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Apremilast for the treatment of psoriatic arthritis.
    Varada S; Tintle SJ; Gottlieb AB
    Expert Rev Clin Pharmacol; 2014 May; 7(3):239-50. PubMed ID: 24702658
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence.
    Dalén J; Svedbom A; Black CM; Lyu R; Ding Q; Sajjan S; Sazonov V; Kachroo S
    Rheumatol Int; 2016 Jul; 36(7):987-95. PubMed ID: 26780533
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Economic impact of biologic utilization patterns in patients with psoriatic arthritis.
    Schwartzman S; Li Y; Zhou H; Palmer JB
    Clin Rheumatol; 2017 Jul; 36(7):1579-1588. PubMed ID: 28474139
    [TBL] [Abstract][Full Text] [Related]  

  • 80. In the Real World: Infections Associated with Biologic and Small Molecule Therapies in Psoriatic Arthritis and Psoriasis.
    Siegel SAR; Winthrop KL
    Curr Rheumatol Rep; 2019 Jun; 21(7):36. PubMed ID: 31172303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.